Morning Briefing on Top Gainers -- Research on GTx Inc., Iridium Communications, Neuralstem, and Idera Pharma

LONDON, May 29, 2014 /PRNewswire/ --

The US markets saw a negative sentiment on Wednesday, May 28, 2014, with the NASDAQ Composite closing at 4,225.08, down 0.28%, the Dow Jones Industrial Average ending the session at 16,633.18, down 0.25% and the S&P 500 finishing 0.11% lower at 1,909.78. During the trading session, five out of ten sectors finished on a lower note. Investor-Edge has initiated coverage on the following equities: GTx Inc. (NASDAQ: GTXI), Iridium Communications Inc. (NASDAQ: IRDM), Neuralstem Inc. (NYSE MKT: CUR) and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free technical research on GTXI, IRDM, CUR and IDRA can be downloaded upon signing up at:

http://www.investor-edge.com/3148-register

GTx Inc.'s stock fluctuated between $1.44 and $1.61 before ending the session 9.72% higher at $1.58. On Wednesday, GTx Inc.'s stock reported a trading volume of 1.11 million shares, above its three months average volume of 0.52 million shares. GTx Inc.'s shares have gained 14.49% in the previous three trading sessions and 19.70% in the last one month. However, the stock has declined 4.24% on YTD basis. The S&P 500 Health Care Sector Index fell by 0.28% during the trading session, while the index has advanced 6.38% on YTD basis. The stock is trading above its 50-day moving average. Further, the stock's 50-day moving average of $1.49 is below its 200-day moving average of $1.73. GTx Inc.'s stock has a Relative Strength Index (RSI) of 51.04. Sign up today to read free research on GTXI at:

http://www.investor-edge.com/3148-GTXI-29May2014.pdf

Shares in Iridium Communications Inc. surged 4.91% on Wednesday, closing the day at $7.90. The stock recorded a trading volume of 2.71 million shares, which was above its three months average volume of 1.36 million shares. The stock oscillated between $7.52 and $7.93 during the trading session. Shares in Iridium Communications Inc. have advanced 6.04% over the previous three trading sessions and 17.56% in the last one month. Moreover, the company's shares have surged 26.38% since the start of this year. The S&P 500 Telecommunication Services Sector Index mapped a gain of 0.42% during the trading session, and the index has charted up 4.14% in the previous one month. The stock is trading above its 50-day and 200-day moving averages of $7.25 and $6.62, respectively. Furthermore, shares of the company traded at a PE ratio of 10.71 and have an RSI of 57.09. Sign up today to read free research on IRDM at:

http://www.investor-edge.com/3148-IRDM-29May2014.pdf

On Wednesday, shares in Neuralstem Inc. recorded a trading volume of 2.21 million shares, which was above its three months average volume of 1.12 million shares. The stock ended the day at $4.35, which was 7.67% above its previous day's closing, and registered an intraday range of $4.09 and $4.50. Neuralstem Inc.'s stock has surged 13.28% in the previous three trading sessions, 13.87% in the last one month and 49.48% on YTD basis. The S&P 500 Health Care Sector Index mapped a loss of 0.28% during the trading session, while the index has advanced 0.36% in the last three trading sessions. The company's stock is trading above its 50-day and 200-day moving averages of $3.86 and $2.98, respectively. Moreover, shares of the company have an RSI of 62.25. Sign up today to read free research on CUR at:

http://www.investor-edge.com/3148-CUR-29May2014.pdf

Shares in Idera Pharmaceuticals Inc. finished Wednesday's session 12.21% higher at $2.94. A total of 2.67 million shares were traded, below its three months average volume of 3.23 million shares. The stock moved between $2.64 and $2.98 during the session. Over the previous three trading sessions and in the last one month, Idera Pharmaceuticals Inc.'s stock has advanced 14.84% and 3.89%, respectively. However, the stock has fallen by 36.50% from the year's start. The S&P 500 Health Care Sector Index declined 0.28% during the trading session, and the index has lost 0.46% in the previous three months. The company's shares are trading below their 50-day and 200-day moving averages of $3.51 and $3.24, respectively. Furthermore, Idera Pharmaceuticals Inc.'s stock has an RSI of 42.71. Sign up today to read free research on IDRA at:

http://www.investor-edge.com/3148-IDRA-29May2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Investor-Edge.com

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED